BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.
In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.
The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 07:00:00 CET | Press release
Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru sit
Uzbekistan's National Payment System HUMO and Ant International’s Alipay+ Partner to Facilitate Cross-Border QR Payments28.10.2025 06:55:00 CET | Press release
HUMO will be the 10th national QR network to partner with Alipay+, enabling its network of Uzbek digital payment apps to make cross-border QR payments across Alipay+’s global merchant ecosystem.The Octomobile app by Octobank, supported by HUMO, will be the first Uzbek e-wallet to be integrated with Alipay+, with more Uzbek e-wallets expected to join by the end of the year.Alipay+ now partners with 40 e-wallets and bank apps and 10 national QR payment schemes and payment systems worldwide, connecting over 100 million merchants to 1.8 billion consumers accounts. Alipay+, Ant International’s global wallet gateway, and HUMO, the national payment system in Uzbekistan, announced the partnership in Beijing to facilitate inbound and outbound cross-border QR payments. The Octomobile app by Octobank will be the first Uzbek e-wallet integrated with Alipay+, with more HUMO-connected local e-wallets and bank apps expected to join by the end of the year. This press release features multimedia. View
e.l.f. Beauty Releases FY2025 Impact Report with Emphasis on ‘the Every’28.10.2025 05:01:00 CET | Press release
Bold new campaign encourages the community to “give an e.l.f.” and join the company in making the world a better place for every eye, lip and face e.l.f. Beauty (NYSE: ELF), a purpose-led, results-driven company on a mission to make the best of beauty accessible to every eye, lip and face, today released its fourth annual Impact Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027352775/en/ e.l.f. Beauty releases 4th annual Impact Report, emphasizing it’s evolved purpose statement: to make the world a better place for every eye, lip and face. The digital-first report is built around the theme of “the every”— a reflection of e.l.f.’s commitment to be a bold disruptor with a kind heart. To amplify the message behind the Impact Report, e.l.f. also launched a bold, international consumer campaign: “Give an e.l.f.” The campaign features voices of kindred spirits and encourages the community to fuel their own sense of pur
Geoswift Integrates with Circle Payments Network to Offer Stablecoin-Powered Real-Time Settlements in Cross-Border Payments28.10.2025 00:04:00 CET | Press release
Geoswift, a leading provider of cross-border payment services and solutions globally, today announced its integration with Circle Payments Network (CPN). Geoswift integrates its banking infrastructure with stablecoin-powered settlement system, enabling real-time, compliant, and cost-efficient B2B payments worldwide. Building on its role as an Originating Financial Institution (OFI) within CPN, Geoswift enables clients to expand into Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251024721293/en/ Raymond Qu, Group CEO and founder of Geoswift, and Sunil Sharma, VP Product Management at Circle, celebrating the partnership in Las Vegas. “Geoswift has built a trusted track record in delivering secure, compliant settlements across Asia Pacific, North America, Europe, and the Middle East. By joining Circle Payments Network, we are modernizing that global reach with real-time stablecoin infrastructure — creating faste
Thredd Enters the Credit Space Partnering with LoanPro to Power Next-Generation Credit Capabilities27.10.2025 22:00:00 CET | Press release
Partnership joins LoanPro’s modern lending and credit capabilities with Thredd’s global card issuance and processing to offer scalable and compliant credit solutions across the U.S. and beyond Thredd, the leading next-generation global payments processor, today announced its selection of LoanPro, the modern credit platform, to underpin Thredd’s new suite of credit solutions for fintechs and financial organizations. The partnership marks a significant milestone in Thredd’s strategy to deliver full-stack embedded issuing and processing capabilities inclusive of credit, debit and prepaid. By integrating LoanPro’s advanced, composable credit infrastructure with Thredd’s next gen real-time card issuance and processing capabilities, including digital wallets and embedded fraud detection, clients will be able to design, launch and scale differentiated credit products with unprecedented speed and personalization. The collaboration leverages LoanPro’s category-leading expertise in powering inno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom